Menu
Recruiting NCT06211868

Redirecting Immune, Lipid and Metabolic Drivers of Early Cardiovascular Disease: The RESET Cohort Study

Observational Cardiovascular Diseases Metabolic Syndrome Non-Alcoholic Fatty Liver Disease

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Digital wearable and AI-human symbiotic lifestyle intervention.
Who it may be relevant to
Registry conditions: Cardiovascular Diseases, Metabolic Syndrome, Non-Alcoholic Fatty Liver Disease. Basic parameters: 40 years — 70 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Singapore
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

Project RESET is a Singapore National Medical Research Council Large Collaborative Grant funded program that brings together a nationwide community of cardiovascular, metabolic, and digital health researchers, as well as clinicians across primary and tertiary care to study the immune, lipid and metabolic drivers of early cardiovascular disease. RESET incorporates a nested randomised controlled trials (RCT) to test the use of a combined digital wearable and AI-human symbiotic lifestyle intervention to halt or reverse the progression of early disease.

Interventions

  • Behavioral Digital wearable and AI-human symbiotic lifestyle intervention
    Digital wearable and AI-human symbiotic lifestyle intervention

Primary outcome measures

  • Major adverse cardiovascular event [Time frame: 5 years]

Eligibility criteria

Inclusion criteria

  • 40-70 years old
  • ASCVD (atherosclerotic cardiovascular disease) score of 5% and higher

Exclusion criteria

  • Previous major cardiovascular disease (myocardial infarction, heart failure, ischemic stroke)
  • Limited life expectancy
  • Other ongoing unstable medical conditions
  • Pregnant women

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Study design

Observational model
Cohort

Study locations

Singapore · 1 center
  • NUS — Singapore

Identifiers

NCT: NCT06211868 · RESET

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗